|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
|
31235758 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI.
|
31570699 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
This study demonstrates that CDX-3379 can inhibit tumor ErbB3 phosphorylation in HNSCC.
|
31308059 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings indicate that evaluation of MET and HER2/HER3 in response to cetuximab in HNSCC patients can provide the rationale of successive line of treatment.
|
30694565 |
2019 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
We and others have demonstrated that cetuximab resistance in HNSCC is driven by alternative receptor tyrosine kinases (RTK), including HER3, MET, and AXL.
|
29792310 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we show that ErbB3 is essential for tumor growth of treatment-naive HNSCC patient-derived xenografts.
|
29305574 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thirteen different histological subtypes were affected by ERBB3 mutations; top ones were colorectal carcinomas (6 patients), non-small cell lung cancers (4 patients, including a squamous cell carcinoma), head and neck squamous cell carcinomas (3 patients) and breast carcinomas (3 patients).
|
29413684 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
|
28910149 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined treatment with cetuximab and MM-121 blocked EGFR and HER3 activities and inhibited the PI3K/AKT and ERK signaling pathways and HNSCC cell growth more effectively than each antibody alone.
|
27358485 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose that NRG1 expression and EGFR activation signatures may enrich for improved efficacy of anti-ErbB3 therapeutic mAb approaches when combined with EGFR-targeting therapies in HNSCC.
|
28723928 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
When EGFR is overexpressed in head and neck squamous cell carcinoma (HNSCC), HER2 and HER3 are also expressed.
|
28939847 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We show that high HRG expression is associated with activated HER3, whereas low HRG expression is associated with low HER3 activation in SCCHN tumors.
|
23468880 |
2013 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
ErbB2 and ErbB3 may have potential as predictive markers and as therapeutic targets for combination therapy in treatment of HNSCC with gefitinib.
|
16818711 |
2006 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In an effort to elucidate the role of ErbB receptors in human head and neck squamous cell carcinoma (HNSCC), expression abnormalities and subcellular localization of epidermal growth factor receptor (EGFR), ErbB2, ErbB3, and ErbB4 were investigated along with EGF and tenascin by immunohistochemistry in 38 carcinomas as compared to adjacent normal mucosa of 24 cases.
|
15476268 |
2004 |
|
Squamous cell carcinoma of the head and neck
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of the c-erbB-2, c-erbB-3 and c-erbB-4 members of the epidermal growth factor receptor family was examined in 16 fresh frozen tissue specimens of SCCHN using avidin-biotin complex immunohistochemistry, with monoclonal and/or polyclonal antibodies directed against each.
|
9494565 |
1998 |